Our findings reveal tumor-intrinsic mechanisms suppressing NK cell activity in NSCLC, proposing XBP1s, IL-6, and UBE2S as actionable targets to enhance NK-based immunotherapies. The gene discussed is IL6; the disease is non-small cell lung carcinoma.